Navigation Links
West to Host Investor Day
Date:3/7/2008

LIONVILLE, Pa., March 7 /PRNewswire-FirstCall/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced that it will conduct a live webcast of its Investor Day event on Thursday, March 13, 2008 from 8:30am to approximately 11:30am EDT. The event will be held at the Grand Hyatt Hotel in New York, New York.

The following members of management will provide an in-depth look at the Company's global operations, business segments, supply chain management and investments in innovation. Speakers will include:
-- Don Morel, Chairman and CEO

-- Steve Ellers, President and COO

-- Mike Schaefers, Director of Marketing, Europe/Asia Pacific

-- John Paproski, Vice President, Innovation

-- Bernie Lahendro, Vice President and General Manager, Daikyo Crystal

Zenith

A live audio webcast and a copy of the presentations will be available through the Investor link of the Company's website, http://www.westpharma.com. A replay of the audio portion will be available for 14 days. To access the live webcast, visit the company's Web site at least 15 minutes prior to the scheduled start time to download any necessary audio or plug-in software.

About West Pharmaceutical Services, Inc.

West Pharmaceutical Services, Inc. is a global manufacturer of components and systems for injectable drug delivery, including stoppers and seals for vials, and closures and disposable components used in syringe, IV and blood collection systems. The Company also provides products with application to the personal care, food and beverage markets. Headquartered in Lionville, Pennsylvania, West Pharmaceutical Services supports its partners and customers fr
'/>"/>

SOURCE West Pharmaceutical Services, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BD to Present at Investor Healthcare Conferences
2. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
3. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Susquehanna Healthcare Conference
4. Kendle to Present at the 29th Annual Raymond James Institutional Investors Conference
5. NuRx Pharmaceuticals Retains Russo Partners for Investor Relations, Corporate Communications Counsel
6. PAREXEL International to Present at Raymond James 29th Annual Institutional Investors Conference
7. Investor Alert from Cauley Bowman Carney & Williams, PLLC: Update on Proposed Acquisition of CollaGenex Pharmaceuticals, Inc. - CGPI
8. CuraGen to Present at the BIO CEO & Investor Conference
9. SemBioSys to present at the 10th Annual BIO CEO & Investor Conference
10. Santaris Pharma to Present at 10th Annual Biotechnology Industry Organisation CEO & Investor Conference - February 11th, 2008
11. Emisphere Technologies to Web Cast BIO CEO & Investor Conference Presentation February 12
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... VANCOUVER , April 27, 2015 /PRNewswire/ - iCo ... ICOTF), today reported financial results for the year ... are expressed in Canadian dollars and presented under ... year,s phase two DME results did not provide ... but extremely undervalued assets remain at iCo Therapeutics", ...
(Date:4/27/2015)... , April 27, 2015  Edico Genome today ... geneticists from Harvard and Stanford Universities showed the ... genome sequence with 300x depth of coverage by ... to 60 hours with standard software. ... challenge, especially for individual research and clinical labs, ...
(Date:4/27/2015)... , April 27, 2015 ... release, please scroll to bottom . ... Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX ), Idera ... Corporation (NASDAQ: SNTA ), Spectrum Pharmaceuticals Inc. ... MDVN ). Free research report on Lexicon ...
(Date:4/27/2015)...  Haemonetics Corporation (NYSE: HAE ) today ... of $226.5 million, down 6%.  Excluding currency impact, ... Company reported a fourth quarter GAAP net loss ... net income, exclusive of transformation, restructuring and deal ... 1%, and adjusted earnings per share were $0.47, ...
Breaking Biology Technology:iCo Therapeutics Announces Year End 2014 Financial Results 2iCo Therapeutics Announces Year End 2014 Financial Results 3iCo Therapeutics Announces Year End 2014 Financial Results 4Edico Genome, in Collaboration with Researchers from Harvard and Stanford Universities, Speeds Analysis of Whole Genome Sequence with 300x Depth of Coverage Tenfold 2Edico Genome, in Collaboration with Researchers from Harvard and Stanford Universities, Speeds Analysis of Whole Genome Sequence with 300x Depth of Coverage Tenfold 3Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 2Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 3Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 4Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 5Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 2Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 3Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 4Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 5Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 6Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 7Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 8Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 9Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 10Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 11Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 12Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 13Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 14Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 15Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 16Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 17Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 18Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 19Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 20Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 21Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 22Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 23Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 24Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 25Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 26Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 27
... (OTCBB: GNLK, "the Company," or "GeneLink"), a leading consumer ... year ended December 31, 2010. Financial Highlights: ... 2009 to $4,997,367 in 2010; Annual net sales ... 2009; Operating losses in 2010 decreased to $2,169,898, a ...
... SEATTLE, April 4, 2011 Omeros Corporation (NASDAQ: ... developing and commercializing products focused on inflammation, bleeding and ... Gregory A. Demopulos, M.D., chairman and chief executive officer, ... Healthcare Conference taking place in New York City this ...
... proteins, polymers, minerals, and engineered materials will be published ... Nature Materials . The discovery by two Penn State ... the structure of materials, which the researchers say greatly ... desired properties. The research is expected to have broad ...
Cached Biology Technology:GeneLink Reports 2010 Results 2Search for advanced materials aided by discovery of hidden symmetries in nature 2Search for advanced materials aided by discovery of hidden symmetries in nature 3
(Date:4/1/2015)... BOSTON , April 1, 2015   Medisafe ... 1.5 million users across iOS and ... has begun integrating biofeedback into the platform to allow ... health outcomes. For the first time, patients will be ... missing a dose impacts important biometrics, such as glucose ...
(Date:3/30/2015)... , Mar. 26, 2015 Research and Markets ... of the "Global Gesture Recognition Market in Automotive ... The analysts forecast the Global Gesture Recognition market in ... over the period 2013-2018. Gesture recognition is ... to different gestures of an individual. Gesture recognition technology ...
(Date:3/24/2015)... and Markets ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ) has announced the addition ... Report" report to their offering. This report analyzes ... by the following Segments: Face Biometrics, and Voice Biometrics. The report ... , Japan , Europe , ... & Africa , and Latin America ...
Breaking Biology News(10 mins):Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6
... specific commitment to the development of European biomedical research ... project in bioinformatics (ELIXIR), biobanking (BBMRI) and translational research ... support preparation and pilot studies in 2010. ... to the building of these European infrastructures. The level ...
... National Academy of Engineering (NAE) and the Institute of ... at the regional meeting and panel discussion on "Engineering ... Hosted by James M. Tien, Ph.D., DEng (h.c.), NAE, ... and Daniel Berg, PhD, NAE, Distinguished Research Professor of ...
... Fla. A 60-million-year-old relative of crocodiles described this ... Journal of Vertebrate Paleontology was likely a food ... ever known. Working with scientists from the Smithsonian ... Museum of Natural History on the UF campus found ...
Cached Biology News:Finland invests €1.85 million in pan-European infrastructure for biomedical research 2Leaders from the National Academies gather to discuss engineering innovations in health care 2UF researchers: Ancient crocodile relative likely food source for Titanoboa 2UF researchers: Ancient crocodile relative likely food source for Titanoboa 3
... raised against a partial recombinant ... HD (NP_002102, 81 a.a. ... protein with GST tag. ... NM_002111 Protein ...
... 220 V, is used for agitation and mixing ... staining and destaining of gels and blots, and ... (8-40 rpm) and can handle a maximum load ... two 29 x 21 cm platforms covered with ...
...
...
Biology Products: